

HR 8454

Medical Marijuana and Cannabidiol Research Expansion Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Crime and Law Enforcement

Introduced: Jul 21, 2022

Current Status: Became Public Law No: 117-215.

Latest Action: Became Public Law No: 117-215. (Dec 2, 2022)

Law: 117-215 (Enacted Dec 2, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/8454>

Sponsor

Name: Rep. Blumenauer, Earl [D-OR-3]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (10 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Jul 21, 2022
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		Jul 21, 2022
Rep. Harris, Andy [R-MD-1]	R · MD		Jul 21, 2022
Rep. Joyce, David P. [R-OH-14]	R · OH		Jul 21, 2022
Rep. Mace, Nancy [R-SC-1]	R · SC		Jul 21, 2022
Rep. Perlmutter, Ed [D-CO-7]	D · CO		Jul 21, 2022
Rep. Cohen, Steve [D-TN-9]	D · TN		Jul 22, 2022
Rep. Dingell, Debbie [D-MI-12]	D · MI		Jul 22, 2022
Rep. Lee, Barbara [D-CA-13]	D · CA		Jul 22, 2022
Rep. Pappas, Chris [D-NH-1]	D · NH		Jul 22, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Jul 21, 2022
Judiciary Committee	House	Referred To	Jul 21, 2022

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

Bill	Relationship	Last Action
117 S 253	Related bill	Mar 28, 2022: Held at the desk.

Medical Marijuana and Cannabidiol Research Expansion Act

This act establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the act directs the Drug Enforcement Administration (DEA) to follow procedures specified in the act to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the act includes various other provisions, including provisions that

- require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
- prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
- allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
- require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.

Actions Timeline

- **Dec 2, 2022:** Signed by President.
- **Dec 2, 2022:** Became Public Law No: 117-215.
- **Nov 29, 2022:** Presented to President.
- **Nov 17, 2022:** Message on Senate action sent to the House.
- **Nov 16, 2022:** Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
- **Nov 16, 2022:** Passed Senate without amendment by Voice Vote. (consideration: CR S6746-6747)
- **Jul 27, 2022:** Received in the Senate, read twice.
- **Jul 26, 2022:** Mr. Pallone moved to suspend the rules and pass the bill, as amended.
- **Jul 26, 2022:** Considered under suspension of the rules. (consideration: CR H7120-7124)
- **Jul 26, 2022:** DEBATE - The House proceeded with forty minutes of debate on H.R. 8454.
- **Jul 26, 2022:** At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
- **Jul 26, 2022:** Considered as unfinished business. (consideration: CR H7145-7146)
- **Jul 26, 2022:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392).(text: CR H7120-7122)
- **Jul 26, 2022:** On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392). (text: CR H7120-7122)
- **Jul 26, 2022:** Motion to reconsider laid on the table Agreed to without objection.
- **Jul 21, 2022:** Introduced in House
- **Jul 21, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.